• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $BRKR

    Bruker Corporation

    Subscribe to $BRKR
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Bruker Corporation develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through three segments: Bruker Scientific Instruments (BSI) Life Science, BSI NANO, and Bruker Energy & Supercon Technologies. It offers life science tools based on magnetic resonance technology; life science mass spectrometry and ion mobility spectrometry solutions; analytical and process analysis instruments and solutions based on infrared and Raman molecular spectroscopy technologies; and radiological/nuclear detectors for chemical, biological, radiological, nuclear, and explosive detection. The company also provides X-ray instruments, atomic force microscopy instrumentation, fluorescence optical microscopy instruments, analytical tools for electron microscopes and X-ray metrology, defect-detection equipment for semiconductor process control, and spark optical emission spectroscopy systems, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments. In addition, it offers superconducting and non-superconducting materials and devices. The company serves academic and government research customers; pharmaceutical and biotechnology, diagnostics, chemical, food and beverage, clinical, nanotechnology, semiconductor, and other industrial companies; nonprofit laboratories; academic institutions and medical schools; contract research organizations; nonprofit and for-profit forensics, and environmental and clinical microbiology laboratories; agriculture, food, and beverage safety laboratories; hospitals and government departments; agencies; raw material manufacturers; and other businesses involved in materials analysis through direct sales forces, distributors, independent sales representatives, and other representatives. Bruker Corporation was incorporated in 1991 and is headquartered in Billerica, Massachusetts.

    IPO Year:

    Exchange: NASDAQ

    Website: bruker.com

    Peers

    $A
    $TMO

    Recent Analyst Ratings for Bruker Corporation

    DatePrice TargetRatingAnalyst
    12/19/2024$72.00Buy
    Guggenheim
    12/10/2024$66.00Neutral
    UBS
    12/5/2024$60.00Sell → Neutral
    Goldman
    10/15/2024$75.00Overweight
    Barclays
    9/30/2024Outperform → Peer Perform
    Wolfe Research
    8/28/2024$78.00Overweight
    Wells Fargo
    6/3/2024$85.00Buy
    Jefferies
    2/14/2024$60.00 → $90.00Neutral → Overweight
    JP Morgan
    12/19/2023$72.00Equal Weight
    Wells Fargo
    12/13/2023$80.00Outperform
    Wolfe Research
    See more ratings

    Bruker Corporation Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Bruker Reports First Quarter 2025 Financial Results

       Q1 2025 revenues of $801.4 million, up 11.0% year-over-year; organic revenue up 2.9%, and constant-exchange rate (CER) revenue up 12.5%; Bruker Scientific Instrument (BSI) segment organic revenue up 5.1% Q1 2025 GAAP diluted EPS $0.11; non-GAAP diluted EPS $0.47, down 11.3% yoy on M&A headwinds Guidance on organic revenue and EPS adjusted for US policy changes and tariff headwinds. Updated FY 2025 guidance: Revenue $3.48 to $3.55 billion, up 3.5% to 5.5%, incl. organic growth of 0% to 2% Non-GAAP EPS $2.40 to $2.48, growth of 0% to 3% yoy Bruker Corporation (NASDAQ:BRKR) today announced financial results for its first quarter ended March 31, 2025. Frank H. Laukien, Bruker's

      5/7/25 7:00:00 AM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Bruker Spatial Biology Pushes Boundaries in Spatial Biology and Multiomics at AACR 2025

      Advancements include CosMx® 2.0 upgrade; CosMx same-slide multiomics; and multiomics capabilities on the nCounter® platform Bruker Corporation (NASDAQ:BRKR) announced today that it will unveil significant advancements in spatial biology and multiomics research at the 2025 American Association for Cancer Research (AACR) General Meeting. These new advancements build upon the innovations announced at AGBT, including launch of CosMx WTX assay for subcellular spatial imaging of the whole transcriptome, the PaintScape™ platform for visualization of 3D genome architecture and chromosomal structure in single cells, the PowerOMX™ engine for streamlined spatial proteomics analysis on the CellScape™

      4/25/25 7:00:00 AM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Bruker to Launch Beacon Discovery™ at AACR 2025, Expanding Access to Live Single-Cell Functional Analysis

      A Compact Benchtop Optofluidic System with Lower Cost of Ownership for Broader Research Accessibility Bruker Corporation (NASDAQ:BRKR) today announced the launch of the Beacon Discovery™ Optofluidic System at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2025. This new Beacon benchtop system offers an accessible entry point into live single-cell functional analysis. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250424150192/en/Beacon Discovery – an accessible, compact system for live single-cell functional analysis Building on Bruker's proprietary Opto-Electrical Positioning (OEP) technology and sc

      4/24/25 7:30:00 AM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Solis Agrosciences Names Crystal Winkeler Chief Business Officer to Drive Commercial Growth

      ST. LOUIS, April 23, 2025 (GLOBE NEWSWIRE) -- Solis Agrosciences, the trusted partner for high-quality AgTech research services, announced that it has hired Crystal Winkeler as Chief Business Officer. Winkeler will join Solis on May 1 to drive the company's commercial team and help lead efforts to develop and acquire new offerings. "Solis has assembled an impressive team, offerings, and customer base," said Winkeler. "I am thrilled to join the business at this important growth stage." "Crystal is a proven talent who is confident, capable, and credible in front of customers and stakeholders," said Charlie Bolten, CEO of Solis Agrosciences. "She is a huge addition and will help drive our c

      4/23/25 6:15:00 AM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Bruker Introduces nVista 2P Miniature Microscope

      Revolutionizing Neural Circuit Imaging in Freely Behaving Animal Research Bruker Corporation (NASDAQ:BRKR) today announced the launch of the nVista 2P miniature, two-photon microscope, a groundbreaking addition to the Inscopix product line for functional imaging of freely behaving animals. It leverages advanced two-photon fluorescence microscopy technology to enable high-resolution imaging at greater depths with 3D data reconstruction, providing researchers with unprecedented insights into neuronal activity. Featuring several innovations in miniscope design, nVista 2P offers enhanced resolution for sub-cellular imaging and mapping of neural circuit dynamics. This press release features mul

      4/17/25 9:00:00 AM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Bruker Announces Majority Acquisition of RECIPE, a Leading Provider of Mass Spectrometry-based Diagnostic Assay Kits for Therapeutic Drug Monitoring

      Bruker and RECIPE are pioneering the high-throughput ‘chrom-free' ClinDART triple-quad MS platform for robust and cost-effective therapeutic drug monitoring assays Bruker Corporation (NASDAQ:BRKR) today announced a majority investment in RECIPE Chemicals + Instruments GmbH, based in Munich, Germany. RECIPE is a leading European provider of vendor-agnostic therapeutic drug monitoring (TDM) and other clinical in vitro diagnostic kits for LC-MS/MS, HPLC, and ICP-MS assays. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250416762711/en/RECIPE kits for clinical laboratories Financial details of the transaction were not disclosed. REC

      4/16/25 6:00:00 AM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Bruker Announces First Quarter 2025 Preliminary Revenue

      Bruker Corporation (NASDAQ:BRKR) today announced preliminary revenue for the first quarter ended March 31, 2025, in a range of $795 million to $800 million, comparing favorably to the Company's earlier outlook and well ahead of consensus. This estimated range implies reported revenue growth of approximately 10% year-over-year, with low-double digit percentage constant exchange rate revenue growth. Bruker estimates non-GAAP organic revenue growth in the first quarter to be in the low-single digit percentages, with mid-single digit percentage organic revenue growth in the Bruker Scientific Instrument (BSI) segment, and a high-teens percentage organic revenue decline in the BEST segment, net

      4/11/25 8:00:00 AM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Bruker Complements Fast, Cost-effective IR Biotyper® Hospital Hygiene Testing and HAI Tracing with NGS Reflex Testing

      Announces majority investment in NGS bioinformatics solution provider Ridom GmbH New NGS microbiology solutions for hygiene testing and epidemiological studies HAI (Hospital-Acquired Infections) tracing with rapid, cost-effective IR Biotyper® testing, followed by selective NGS reflex testing for confirmation and phylogeny Unique workflow with MALDI Biotyper®-based microbial species identification followed by selective NGS-based strain determination and detailed genomic analysis At the ESCMID Global 2025 conference, Bruker´s Microbiology and Infection Diagnostics division is announcing the expansion of its microbiology solutions into Next-Generation Sequencing (NGS) applications, wi

      4/11/25 6:00:00 AM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Bruker Announces First-of-a-kind 1.3 GHz High-Resolution NMR System

      Novel hybrid LTS-HTS superconducting magnet enables high-resolution for liquids and solids ultra-high field NMR research in biomolecular and advanced materials sciences At the Joint ENC-ISMAR Conference 2025, Bruker Corporation, the leading provider of Nuclear Magnetic Resonance (NMR) spectroscopy solutions, announced the successful development and testing of the world's first high-resolution 1.3 GHz NMR spectrometer with a stable, standard-bore 54 mm superconducting magnet. This first-of-a-kind ultra-high field magnet and spectrometer pushes the boundaries of what is possible in the field of NMR research and opens a new chapter of ultra-high field NMR with even higher dispersion and resol

      4/7/25 7:01:00 AM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Bruker Introduces Innovative Fourier 80 Multinuclear Benchtop FT-NMR

      Unique Fourier 80 ‘Multi-Talent' offers 1H NMR and choice of 15 X-nuclei with just one click At the Joint ENC-ISMAR Conference 2025, Bruker Corporation, the leading provider of Nuclear Magnetic Resonance (NMR) spectroscopy solutions, announced the launch of an innovative Fourier 80 multinuclear benchtop FT-NMR spectrometer, known as the ‘Multi-Talent' configuration. This novel Fourier 80 ‘Multi-Talent' system represents a major advancement in permanent magnet-based FT-NMR technology, as its unique, next-generation capabilities meet the evolving needs of academic researchers and industry scientists with dramatically enhanced versatility in benchtop FT-NMR multinuclear analysis. This press r

      4/7/25 7:00:00 AM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    Bruker Corporation Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Accounting Officer Bures Thomas bought $23,698 worth of shares (500 units at $47.40), increasing direct ownership by 17% to 3,472 units (SEC Form 4)

      4 - BRUKER CORP (0001109354) (Issuer)

      3/11/25 4:11:27 PM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • PRESIDENT & CEO Laukien Frank H bought $1,018,330 worth of shares (20,000 units at $50.92), increasing direct ownership by 0.05% to 38,459,563 units (SEC Form 4)

      4 - BRUKER CORP (0001109354) (Issuer)

      2/19/25 4:23:26 PM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • PRESIDENT & CEO Laukien Frank H bought $5,014,069 worth of shares (100,000 units at $50.14), increasing direct ownership by 0.26% to 38,439,563 units (SEC Form 4)

      4 - BRUKER CORP (0001109354) (Issuer)

      11/19/24 4:07:19 PM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    Bruker Corporation Leadership Updates

    Live Leadership Updates

    See more
    • Solis Agrosciences Names Crystal Winkeler Chief Business Officer to Drive Commercial Growth

      ST. LOUIS, April 23, 2025 (GLOBE NEWSWIRE) -- Solis Agrosciences, the trusted partner for high-quality AgTech research services, announced that it has hired Crystal Winkeler as Chief Business Officer. Winkeler will join Solis on May 1 to drive the company's commercial team and help lead efforts to develop and acquire new offerings. "Solis has assembled an impressive team, offerings, and customer base," said Winkeler. "I am thrilled to join the business at this important growth stage." "Crystal is a proven talent who is confident, capable, and credible in front of customers and stakeholders," said Charlie Bolten, CEO of Solis Agrosciences. "She is a huge addition and will help drive our c

      4/23/25 6:15:00 AM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Bruker Appoints Laura Francis to its Board of Directors

      Bruker Corporation (NASDAQ:BRKR) today announced that its Board of Directors has appointed Laura Francis to serve on its board as an independent director, effective as of February 18, 2025. Ms. Francis is also expected to join Bruker's Audit Committee as a financial expert after Bruker's annual shareholder meeting at the end of May 2025. Laura Francis is the Chief Executive Officer and a Board Member of SI-BONE, Inc. (NASDAQ:SIBN), a medical device company solving musculoskeletal disorders of the sacropelvic anatomy. She was previously the Chief Financial Officer and Chief Operating Officer of the company. Prior to joining SI-BONE, Ms. Francis held other executive and leadership roles with

      2/21/25 8:00:00 AM ET
      $BRKR
      $PGNY
      $SIBN
      $SWAV
      Biotechnology: Laboratory Analytical Instruments
      Industrials
      Misc Health and Biotechnology Services
      Health Care
    • Biognosys and Alamar Biosciences Forge Strategic Partnership in Proteomics to Advance Biopharma and Precision Medicine Research

      Strategic partnership expands Biognosys' services to include Alamar's NULISA assays as well as joint scientific research in biofluid-based proteomicsComplementary value of Biognosys' DIA-MS unbiased proteomics platform and Alamar's game-changing immunoassay platforms to be presented at the AACR 2024 Annual Meeting ZURICH, Switzerland and FREMONT, Calif., April 04, 2024 (GLOBE NEWSWIRE) -- Biognosys, a global leader in mass spectrometry-based proteomics, and Alamar Biosciences, Inc., a company powering precision proteomics to enable the earliest detection of disease, are pleased to announce a strategic partnership aimed at advancing scientific discovery in the field of biofluid proteomic

      4/4/24 8:11:00 AM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Bruker Announces Share Purchase Agreement to Acquire Molecular Diagnostics Innovator ELITechGroup

      ELITechGroup is a differentiated, fast growing and profitable systems and assay provider for molecular diagnostics (MDx), biomedical systems/specialty IVD, and microbiology ELITechGroup offers the proprietary, fully automated sample-to-answer (S2A) molecular diagnostic (MDx) systems InGenius® and BeGenius® for mid-sized hospitals and esoteric testing Large and diversified ELITech MDx assay portfolio is focused on pathogens and viral disease ELITechGroup has its R&D, manufacturing and commercial focus on Europe and the Americas Bruker to acquire ELITechGroup revenues of ~Euro 150 million p.a. with >80% consumables revenue Bruker Corporation (NASDAQ:BRKR) announced today that

      2/28/24 7:00:00 AM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Bruker Announces Agreement to Acquire Chemspeed

      Chemspeed Accelerates Bruker's Laboratory Automation and Digitalization Drive Bruker Corporation (NASDAQ:BRKR) today announced a definitive agreement for the acquisition of Chemspeed Technologies AG, a Swiss provider of vendor-agnostic automated laboratory R&D and QC workflow solutions. Chemspeed is focused on modular automation and robotics solutions for chemical research, pharma drug formulation, materials research for cleantech and consumer applications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240125759758/en/Chemspeed's modular, compact FLEX automation workstations enhance chemical and materials science R&D and lab

      1/25/24 7:00:00 AM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Bruker Announces Acquisition of Tornado Spectral Systems to Expand Its Biopharma Process Analytical Technology (PAT) Product Portfolio

      Bruker (NASDAQ:BRKR) today announced the acquisition of Tornado Spectral Systems Inc., a Canadian company specializing in process Raman instruments, primarily used in pharma and biotech quality control applications. Tornado, with over a decade of experience in innovative and industry-proven Raman solutions, will enhance Bruker's biopharma PAT portfolio with its well-established products. Financial details were not disclosed. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240104658012/en/Tornado's proprietary product, the Process Guardian™, which offers superior performance for RAMAN biopharma process applications (Photo: Busines

      1/4/24 8:00:00 AM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Bruker Acquires Electron Microscopy Company Nion

      High-end STEM Technology Expands Bruker's Portfolio for Materials Science Research Bruker today announced that it has acquired Nion, a privately-held company that develops and manufactures innovative high-end scanning transmission electron microscopes (STEM). Nion was the first company to introduce aberration correction for STEM instruments with ultra-high stability for highest resolution images, and Nion is the world leader in ultra-high energy and spatial resolution electron energy-loss spectroscopy (EELS). This acquisition enhances Bruker's product offerings and technology portfolio in materials science research and provides the technology base for applications in electron diffraction

      1/3/24 7:00:00 AM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Bruker Appoints Philip Ma to its Board of Directors

      Bruker Corporation (NASDAQ:BRKR) today announced that its Board of Directors has appointed Philip Ma, Ph.D. to serve on its board, effective as of April 1, 2022. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220316005639/en/Dr. Philip Ma is Chief Executive Officer, President, and Founder of PrognomiQ (Photo: Business Wire) Dr. Ma is Chief Executive Officer, founder, and a director of PrognomiQ, a privately held healthcare company that is developing next-generation, transformative multiomics products to enable early cancer detection and cancer treatment selection and monitoring assays. Before PrognomiQ, Dr. Ma was Chief Business

      3/16/22 9:46:00 AM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    Bruker Corporation Financials

    Live finance-specific insights

    See more
    • Bruker Reports First Quarter 2025 Financial Results

       Q1 2025 revenues of $801.4 million, up 11.0% year-over-year; organic revenue up 2.9%, and constant-exchange rate (CER) revenue up 12.5%; Bruker Scientific Instrument (BSI) segment organic revenue up 5.1% Q1 2025 GAAP diluted EPS $0.11; non-GAAP diluted EPS $0.47, down 11.3% yoy on M&A headwinds Guidance on organic revenue and EPS adjusted for US policy changes and tariff headwinds. Updated FY 2025 guidance: Revenue $3.48 to $3.55 billion, up 3.5% to 5.5%, incl. organic growth of 0% to 2% Non-GAAP EPS $2.40 to $2.48, growth of 0% to 3% yoy Bruker Corporation (NASDAQ:BRKR) today announced financial results for its first quarter ended March 31, 2025. Frank H. Laukien, Bruker's

      5/7/25 7:00:00 AM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Bruker Announces First Quarter 2025 Preliminary Revenue

      Bruker Corporation (NASDAQ:BRKR) today announced preliminary revenue for the first quarter ended March 31, 2025, in a range of $795 million to $800 million, comparing favorably to the Company's earlier outlook and well ahead of consensus. This estimated range implies reported revenue growth of approximately 10% year-over-year, with low-double digit percentage constant exchange rate revenue growth. Bruker estimates non-GAAP organic revenue growth in the first quarter to be in the low-single digit percentages, with mid-single digit percentage organic revenue growth in the Bruker Scientific Instrument (BSI) segment, and a high-teens percentage organic revenue decline in the BEST segment, net

      4/11/25 8:00:00 AM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Bruker Announces Quarterly Dividend

      Bruker Corporation (NASDAQ:BRKR) today announced that its Board of Directors has approved payment of a quarterly cash dividend in the amount of $0.05 per share on the Company's common stock. The dividend will be paid on March 28, 2025 to stockholders of record as of March 17, 2025. About Bruker Corporation – Leader of the Post-Genomic Era (NASDAQ:BRKR) Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life. Bruker's high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microsc

      2/21/25 7:00:00 AM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Bruker Announces Date and Time of Fourth Quarter 2024 Earnings Release and Webcast

      Bruker Corporation (NASDAQ:BRKR) today announced it will report fourth quarter and fiscal year 2024 financial results before market opening on Thursday, February 13, 2025. The Company will host a conference call and webcast at 8:30 a.m. Eastern Standard Time to discuss the results and current business trends. To listen to the webcast, investors can go to https://ir.bruker.com and click on the "Q4 2024 Earnings Webcast" hyperlink in the "Events & Presentations" section. A slide presentation will be referenced during the webcast and will be posted to the Company's website shortly before the webcast begins. Investors can also listen to the earnings webcast via telephone by dialing 1-888-43

      2/7/25 7:00:00 AM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Bruker Announces Quarterly Dividend

      Bruker Corporation (NASDAQ:BRKR) today announced that its Board of Directors has approved payment of a quarterly cash dividend in the amount of $0.05 per share on the Company's common stock. The dividend will be paid on December 16, 2024 to stockholders of record as of December 2, 2024. About Bruker Corporation – Leader of the Post-Genomic Era (NASDAQ:BRKR) Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life. Bruker's high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and

      11/18/24 7:00:00 AM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Bruker Announces Date and Time of Third Quarter 2024 Earnings Release and Webcast

      Bruker Corporation (NASDAQ:BRKR) today announced it will report third quarter 2024 financial results before market opening on Tuesday, November 5, 2024. The Company will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss the results and current business trends. To listen to the webcast, investors can go to https://ir.bruker.com and click on the "Q3 2024 Earnings Webcast" hyperlink in the "Events & Presentations" section. A slide presentation will be referenced during the webcast and will be posted to the Company's website shortly before the webcast begins. Investors can also listen to the earnings webcast via telephone by dialing 1-888-437-2685 (U.S. toll free) or +1-

      10/28/24 4:05:00 PM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Bruker Acquires Dynamic Biosensors, a Pioneer of Single-Cell Interaction Cytometry Systems for Drug Discovery

      Combining Dynamic Biosensors' Innovative Technologies with Bruker's High-Performance SPR Portfolio to Establish a Leading Biosensors Business Bruker Corporation (NASDAQ:BRKR) today announced the acquisition of Dynamic Biosensors GmbH, a pioneering company known for its breakthroughs in biosensor development, which is based in Munich, Germany. This acquisition strengthens Bruker's biophysical portfolio for the analysis of molecular interactions and kinetics, offering deeper insights into both inter-molecular and molecule-single cell interactions in drug discovery or basic research. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/202

      10/2/24 7:00:00 AM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Bruker Announces Quarterly Dividend

      Bruker Corporation (NASDAQ:BRKR) today announced that its Board of Directors has approved payment of a quarterly cash dividend in the amount of $0.05 per share on the Company's common stock. The dividend will be paid on September 16, 2024 to stockholders of record as of September 2, 2024. About Bruker Corporation – Leader of the Post-Genomic Era (NASDAQ:BRKR) Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life. Bruker's high-performance scientific instruments and high-value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, an

      8/12/24 7:00:00 AM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Bruker Reports Second Quarter 2024 Financial Results

      Q2 2024 revenues of $800.7 million, up 17.4% year-over-year (yoy); organic revenue up 7.4% yoy; CER revenue up 18.5% yoy Q2 2024 GAAP EPS $0.05; non-GAAP EPS $0.52, up 4.0% yoy Bruker increases FY 2024 revenue guidance to $3.38-$3.44 billion, now including the NanoString business; implies revenue growth of 14% to 16%, and organic revenue growth of 5% to 7% yoy Bruker Corporation (NASDAQ:BRKR) today announced financial results for its second quarter and for the six months ended June 30, 2024. Frank H. Laukien, Bruker's President and CEO, commented: "Our teams delivered excellent revenue growth in the second quarter and a solid first half of 2024, despite soft general market condi

      8/6/24 7:00:00 AM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Bruker Announces Date and Time of Second Quarter 2024 Earnings Release and Webcast

      Bruker Corporation (NASDAQ:BRKR) today announced it will report second quarter 2024 financial results before market opening on Tuesday, August 6, 2024. The Company will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss the results and current business trends. To listen to the webcast, investors can go to https://ir.bruker.com and click on the "Q2 2024 Earnings Webcast" hyperlink in the "Events & Presentations" section. A slide presentation will be referenced during the webcast and will be posted to the Company's website shortly before the webcast begins. Investors can also listen to the earnings webcast via telephone by dialing 1-888-437-2685 (U.S. toll free) or +1

      7/31/24 4:05:00 PM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    Bruker Corporation Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Bruker Corporation

      SC 13G/A - BRUKER CORP (0001109354) (Subject)

      11/14/24 1:28:29 PM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Amendment: SEC Form SC 13G/A filed by Bruker Corporation

      SC 13G/A - BRUKER CORP (0001109354) (Subject)

      11/13/24 6:01:26 PM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Amendment: SEC Form SC 13G/A filed by Bruker Corporation

      SC 13G/A - BRUKER CORP (0001109354) (Subject)

      11/12/24 11:54:03 AM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Amendment: SEC Form SC 13G/A filed by Bruker Corporation

      SC 13G/A - BRUKER CORP (0001109354) (Subject)

      11/12/24 9:50:14 AM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SC 13G/A filed by Bruker Corporation (Amendment)

      SC 13G/A - BRUKER CORP (0001109354) (Subject)

      2/14/24 10:04:34 AM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SC 13G/A filed by Bruker Corporation (Amendment)

      SC 13G/A - BRUKER CORP (0001109354) (Subject)

      2/13/24 5:00:53 PM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SC 13G/A filed by Bruker Corporation (Amendment)

      SC 13G/A - BRUKER CORP (0001109354) (Subject)

      2/9/24 11:49:03 AM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SC 13G/A filed by Bruker Corporation (Amendment)

      SC 13G/A - BRUKER CORP (0001109354) (Subject)

      2/9/24 8:50:22 AM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SC 13G/A filed by Bruker Corporation (Amendment)

      SC 13G/A - BRUKER CORP (0001109354) (Subject)

      2/14/23 12:40:49 PM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SC 13G/A filed by Bruker Corporation (Amendment)

      SC 13G/A - BRUKER CORP (0001109354) (Subject)

      2/9/23 9:59:38 AM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    Bruker Corporation Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Guggenheim initiated coverage on Bruker with a new price target

      Guggenheim initiated coverage of Bruker with a rating of Buy and set a new price target of $72.00

      12/19/24 7:30:10 AM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • UBS initiated coverage on Bruker with a new price target

      UBS initiated coverage of Bruker with a rating of Neutral and set a new price target of $66.00

      12/10/24 8:26:42 AM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Bruker upgraded by Goldman with a new price target

      Goldman upgraded Bruker from Sell to Neutral and set a new price target of $60.00

      12/5/24 7:35:59 AM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Barclays initiated coverage on Bruker with a new price target

      Barclays initiated coverage of Bruker with a rating of Overweight and set a new price target of $75.00

      10/15/24 7:28:00 AM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Bruker downgraded by Wolfe Research

      Wolfe Research downgraded Bruker from Outperform to Peer Perform

      9/30/24 7:39:59 AM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Wells Fargo initiated coverage on Bruker with a new price target

      Wells Fargo initiated coverage of Bruker with a rating of Overweight and set a new price target of $78.00

      8/28/24 7:37:26 AM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Jefferies resumed coverage on Bruker with a new price target

      Jefferies resumed coverage of Bruker with a rating of Buy and set a new price target of $85.00

      6/3/24 8:41:18 AM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Bruker upgraded by JP Morgan with a new price target

      JP Morgan upgraded Bruker from Neutral to Overweight and set a new price target of $90.00 from $60.00 previously

      2/14/24 6:15:03 AM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Wells Fargo initiated coverage on Bruker with a new price target

      Wells Fargo initiated coverage of Bruker with a rating of Equal Weight and set a new price target of $72.00

      12/19/23 6:46:01 AM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Wolfe Research initiated coverage on Bruker with a new price target

      Wolfe Research initiated coverage of Bruker with a rating of Outperform and set a new price target of $80.00

      12/13/23 6:51:30 AM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    Bruker Corporation SEC Filings

    See more
    • SEC Form 10-Q filed by Bruker Corporation

      10-Q - BRUKER CORP (0001109354) (Filer)

      5/7/25 4:04:14 PM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Bruker Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - BRUKER CORP (0001109354) (Filer)

      5/7/25 7:00:10 AM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form DEF 14A filed by Bruker Corporation

      DEF 14A - BRUKER CORP (0001109354) (Filer)

      4/11/25 4:28:51 PM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Bruker Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - BRUKER CORP (0001109354) (Filer)

      4/11/25 8:00:10 AM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form 10-K filed by Bruker Corporation

      10-K - BRUKER CORP (0001109354) (Filer)

      3/3/25 4:27:32 PM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Bruker Corporation filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

      8-K - BRUKER CORP (0001109354) (Filer)

      2/21/25 8:00:08 AM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Bruker Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - BRUKER CORP (0001109354) (Filer)

      2/13/25 7:00:10 AM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Bruker Corporation filed SEC Form 8-K: Leadership Update

      8-K - BRUKER CORP (0001109354) (Filer)

      1/16/25 5:10:12 PM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Bruker Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure

      8-K - BRUKER CORP (0001109354) (Filer)

      1/13/25 11:06:28 AM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Bruker Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - BRUKER CORP (0001109354) (Filer)

      11/5/24 7:00:10 AM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    Bruker Corporation Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Linton William A exercised 10,000 shares at a strike of $24.00, increasing direct ownership by 21% to 58,723 units (SEC Form 4)

      4 - BRUKER CORP (0001109354) (Issuer)

      4/24/25 4:15:05 PM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Chief Accounting Officer Bures Thomas bought $23,698 worth of shares (500 units at $47.40), increasing direct ownership by 17% to 3,472 units (SEC Form 4)

      4 - BRUKER CORP (0001109354) (Issuer)

      3/11/25 4:11:27 PM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form 3 filed by new insider Francis Laura

      3 - BRUKER CORP (0001109354) (Issuer)

      2/19/25 4:40:27 PM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Chief Accounting Officer Bures Thomas was granted 2,972 shares (SEC Form 4)

      4 - BRUKER CORP (0001109354) (Issuer)

      2/19/25 4:39:42 PM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Director Rosenthal Bob was granted 3,298 shares, increasing direct ownership by 11% to 34,261 units (SEC Form 4)

      4 - BRUKER CORP (0001109354) (Issuer)

      2/19/25 4:38:52 PM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Director Requardt Hermann Fritz was granted 3,298 shares, increasing direct ownership by 14% to 26,445 units (SEC Form 4)

      4 - BRUKER CORP (0001109354) (Issuer)

      2/19/25 4:37:59 PM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Director Perkins Adelene Q was granted 3,298 shares, increasing direct ownership by 15% to 24,624 units (SEC Form 4)

      4 - BRUKER CORP (0001109354) (Issuer)

      2/19/25 4:37:03 PM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Director Packer Richard A was granted 3,298 shares, increasing direct ownership by 4% to 84,202 units (SEC Form 4)

      4 - BRUKER CORP (0001109354) (Issuer)

      2/19/25 4:36:06 PM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Director Ornell John A was granted 3,298 shares, increasing direct ownership by 14% to 26,445 units (SEC Form 4)

      4 - BRUKER CORP (0001109354) (Issuer)

      2/19/25 4:27:45 PM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Director Linton William A was granted 3,298 shares, increasing direct ownership by 7% to 48,723 units (SEC Form 4)

      4 - BRUKER CORP (0001109354) (Issuer)

      2/19/25 4:26:48 PM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials